| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | risperidone (Okedi®) |
| Formulation | 75 mg and 100 mg powder and solvent for prolonged-release suspension for injection |
| Reference number | 5100 |
| Indication | Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone |
| Company | Rovi Biotech Limited |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 04/04/2022 |